Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases and Clinical Research Centre, Hvidovre Hospital, and Department of International Health, Immunology, and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases and Clinical Research Centre, Hvidovre Hospital, and Department of International Health, Immunology, and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Trends Microbiol. 2014 Jun;22(6):354-64. doi: 10.1016/j.tim.2014.02.005. Epub 2014 Mar 11.
Genetic recombination is an important evolutionary mechanism for RNA viruses. The significance of this phenomenon for hepatitis C virus (HCV) has recently become evident, with the identification of circulating recombinant forms in HCV-infected individuals and by novel data from studies permitted by advances in HCV cell culture systems and genotyping protocols. HCV is readily able to produce viable recombinants, using replicative and non-replicative molecular mechanisms. However, our knowledge of the required molecular mechanisms remains limited. Understanding how HCV recombines might be instrumental for a better monitoring of global epidemiology, to clarify the virus evolution, and evaluate the impact of recombinant forms on the efficacy of oncoming combination drug therapies. For the latter, frequency and location of recombination events could affect the efficacy of multidrug regimens. This review will focus on current data available on HCV recombination, also in relation to more detailed data from other RNA viruses.
遗传重组是 RNA 病毒的一种重要进化机制。最近，丙型肝炎病毒 (HCV) 中的这一现象的重要性变得明显，这是通过鉴定 HCV 感染者的循环重组形式，以及通过 HCV 细胞培养系统和基因分型方案的进步所允许的新数据得出的。HCV 很容易通过复制和非复制分子机制产生有活力的重组体。然而，我们对所需分子机制的了解仍然有限。了解 HCV 如何重组可能有助于更好地监测全球流行病学，阐明病毒进化，并评估重组形式对即将到来的联合药物治疗效果的影响。对于后者，重组事件的频率和位置可能会影响多药治疗方案的效果。这篇综述将重点介绍关于 HCV 重组的现有数据，也将涉及其他 RNA 病毒的更详细数据。
